FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169246527> ?p ?o ?g. }

• W3169246527 endingPage "e1008" @default.
• W3169246527 startingPage "e999" @default.
• W3169246527 abstract "BackgroundStaging and treatment of human African trypanosomiasis caused by Trypanosoma brucei gambiense (g-HAT) required lumbar puncture to assess cerebrospinal fluid (CSF) and intravenous drugs that cross the blood–brain barrier for late-stage infection. These procedures are inconvenient in rural health systems of disease-endemic countries. A pivotal study established fexinidazole as the first oral monotherapy to be effective against non-severe stage 2 g-HAT. We aimed to assess the safety and efficacy of fexinidazole in early g-HAT.MethodsIn this prospective, multicentre, open-label, single-arm cohort study, patients with stage 1 or early stage 2 g-HAT were recruited from eight treatment centres in the Democratic Republic of the Congo. Primary inclusion criteria included being older than 15 years, being able to ingest at least one complete meal per day (or at least one sachet of Plumpy'Nut®), a Karnofsky score higher than 50, evidence of trypanosomes in the blood or lymph but no evidence of trypanosomes in the CSF, willingness to be admitted to hospital to receive treatment, having a permanent address, and being able to comply with the follow-up visit schedule. Exclusion criteria included severe malnutrition, inability to take medication orally, pregnant or breastfeeding women, any clinically important medical condition that could jeopardise patient safety or participation in the study, severely deteriorated general status, any contraindication to imidazole drugs, HAT treatment in the past 2 years, previous enrolment in the study or previous intake of fexinidazole, abnormalities on electrocardiogram that did not return to normal in pretreatment repeated assessments or were considered clinically important, QT interval corrected using Fridericia's formula of at least 450 ms, and patients not tested for malaria or not having received appropriate treatment for malaria or for soil-transmitted helminthiasis. Patients were classified into stage 1 or early stage 2 g-HAT groups following evidence of trypanosomes in the blood, lymph, and absence in CSF, and using white-blood-cell count in CSF. Patients received 1800 mg fexinidazole once per day on days 1–4 then 1200 mg fexinidazole on days 5–10. Patients were observed for approximately 19 months in total. Study participants were followed up on day 5 and day 8 during treatment, at end of treatment on day 11, at end of hospitalisation on days 11–18, at week 9 for a subset of patients, and after 6 months, 12 months, and 18 months. The primary endpoint was treatment success at 12 months. Safety was assessed through routine monitoring. Analyses were done in the intention-to-treat population. The acceptable success rate was defined as treatment efficacy in more than 80% of patients. This study is completed and registered with ClinicalTrials.gov (NCT02169557).FindingsPatients were enrolled between April 30, 2014, and April 25, 2017. 238 patients were recruited: 195 (82%) patients with stage 1 g-HAT and 43 (18%) with early stage 2 g-HAT. 189 (97%) of 195 patients with stage 1 g-HAT and 41 (95%) of 43 patients with early stage 2 g-HAT were finally included and completed the 10 day treatment period. Three patients with stage 1 g-HAT died after the 10 day treatment period and before the 12 month primary follow-up visit, considered as treatment failure and were withdrawn from the study. Treatment was effective at 12 months for 227 (99%) of 230 patients (95% CI 96·2–99·7): 186 (98%) of 189 patients (95·4–99·7) with stage 1 and 41 (100%) of 41 patients (91·4–100·0) with early stage 2, indicating that the primary study endpoint was met. No new safety issues were observed. The most frequent adverse events were headache and vomiting. In total, 214 (93%) of 230 patients had treatment-emergent adverse events, mainly common-terminology criteria for adverse events grades 1 to 3. None led to treatment discontinuation.InterpretationFexinidazole is a valuable first-line treatment option in the early stages of g-HAT.FundingThrough the Drugs for Neglected Diseases initiative: the Bill & Melinda Gates Foundation, the Republic and Canton of Geneva (Switzerland), the Dutch Ministry of Foreign Affairs (also known as DGIS; Netherlands), the Norwegian Agency for Development Cooperation (also known as Norad; Norway), the Federal Ministry of Education and Research (also known as BMBF) through KfW (Germany), the Brian Mercer Charitable Trust (UK), and other private foundations and individuals from the HAT campaign.TranslationFor the French translation of the abstract see Supplementary Materials section." @default.
• W3169246527 created "2021-06-22" @default.
• W3169246527 creator A5002744107 @default.
• W3169246527 creator A5010865484 @default.
• W3169246527 creator A5011160351 @default.
• W3169246527 creator A5011819254 @default.
• W3169246527 creator A5017173339 @default.
• W3169246527 creator A5018342398 @default.
• W3169246527 creator A5023585185 @default.
• W3169246527 creator A5023745735 @default.
• W3169246527 creator A5027256306 @default.
• W3169246527 creator A5030878686 @default.
• W3169246527 creator A5032281855 @default.
• W3169246527 creator A5037759663 @default.
• W3169246527 creator A5040181163 @default.
• W3169246527 creator A5041516138 @default.
• W3169246527 creator A5049897250 @default.
• W3169246527 creator A5059850661 @default.
• W3169246527 creator A5063812112 @default.
• W3169246527 creator A5070335873 @default.
• W3169246527 creator A5076945656 @default.
• W3169246527 creator A5077931859 @default.
• W3169246527 creator A5079174875 @default.
• W3169246527 creator A5081156142 @default.
• W3169246527 creator A5087795656 @default.
• W3169246527 creator A5090892765 @default.
• W3169246527 date "2021-07-01" @default.
• W3169246527 modified "2023-10-05" @default.
• W3169246527 title "Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study" @default.
• W3169246527 cites W1530546868 @default.
• W3169246527 cites W1972288788 @default.
• W3169246527 cites W2036763008 @default.
• W3169246527 cites W2077451644 @default.
• W3169246527 cites W2097156911 @default.
• W3169246527 cites W2104765579 @default.
• W3169246527 cites W2110499439 @default.
• W3169246527 cites W2151799620 @default.
• W3169246527 cites W2159681243 @default.
• W3169246527 cites W2556792541 @default.
• W3169246527 cites W2765696050 @default.
• W3169246527 doi "https://doi.org/10.1016/s2214-109x(21)00208-4" @default.
• W3169246527 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8220131" @default.
• W3169246527 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34143998" @default.
• W3169246527 hasPublicationYear "2021" @default.
• W3169246527 type Work @default.
• W3169246527 sameAs 3169246527 @default.
• W3169246527 citedByCount "32" @default.
• W3169246527 countsByYear W31692465272021 @default.
• W3169246527 countsByYear W31692465272022 @default.
• W3169246527 countsByYear W31692465272023 @default.
• W3169246527 crossrefType "journal-article" @default.
• W3169246527 hasAuthorship W3169246527A5002744107 @default.
• W3169246527 hasAuthorship W3169246527A5010865484 @default.
• W3169246527 hasAuthorship W3169246527A5011160351 @default.
• W3169246527 hasAuthorship W3169246527A5011819254 @default.
• W3169246527 hasAuthorship W3169246527A5017173339 @default.
• W3169246527 hasAuthorship W3169246527A5018342398 @default.
• W3169246527 hasAuthorship W3169246527A5023585185 @default.
• W3169246527 hasAuthorship W3169246527A5023745735 @default.
• W3169246527 hasAuthorship W3169246527A5027256306 @default.
• W3169246527 hasAuthorship W3169246527A5030878686 @default.
• W3169246527 hasAuthorship W3169246527A5032281855 @default.
• W3169246527 hasAuthorship W3169246527A5037759663 @default.
• W3169246527 hasAuthorship W3169246527A5040181163 @default.
• W3169246527 hasAuthorship W3169246527A5041516138 @default.
• W3169246527 hasAuthorship W3169246527A5049897250 @default.
• W3169246527 hasAuthorship W3169246527A5059850661 @default.
• W3169246527 hasAuthorship W3169246527A5063812112 @default.
• W3169246527 hasAuthorship W3169246527A5070335873 @default.
• W3169246527 hasAuthorship W3169246527A5076945656 @default.
• W3169246527 hasAuthorship W3169246527A5077931859 @default.
• W3169246527 hasAuthorship W3169246527A5079174875 @default.
• W3169246527 hasAuthorship W3169246527A5081156142 @default.
• W3169246527 hasAuthorship W3169246527A5087795656 @default.
• W3169246527 hasAuthorship W3169246527A5090892765 @default.
• W3169246527 hasBestOaLocation W31692465271 @default.
• W3169246527 hasConcept C126322002 @default.
• W3169246527 hasConcept C142724271 @default.
• W3169246527 hasConcept C146357865 @default.
• W3169246527 hasConcept C151730666 @default.
• W3169246527 hasConcept C187212893 @default.
• W3169246527 hasConcept C188816634 @default.
• W3169246527 hasConcept C203014093 @default.
• W3169246527 hasConcept C204787440 @default.
• W3169246527 hasConcept C2776494729 @default.
• W3169246527 hasConcept C2778143080 @default.
• W3169246527 hasConcept C2778792689 @default.
• W3169246527 hasConcept C71924100 @default.
• W3169246527 hasConcept C72563966 @default.
• W3169246527 hasConcept C86803240 @default.
• W3169246527 hasConceptScore W3169246527C126322002 @default.
• W3169246527 hasConceptScore W3169246527C142724271 @default.
• W3169246527 hasConceptScore W3169246527C146357865 @default.
• W3169246527 hasConceptScore W3169246527C151730666 @default.
• W3169246527 hasConceptScore W3169246527C187212893 @default.
• W3169246527 hasConceptScore W3169246527C188816634 @default.
• W3169246527 hasConceptScore W3169246527C203014093 @default.
• W3169246527 hasConceptScore W3169246527C204787440 @default.

• next